Roschier advised Sedana Medical and Pareto Securities on Sedana’s private placement of new shares
Sedana Medical AB (publ) has completed a directed new share issue, raising proceeds of SEK 375 million. Roschier represented Sedana Medical and Sedana Medical’s financial advisor Pareto Securities AB in connection with the transaction.
The SEK 375 million private placement of new shares was executed through an accelerated book-building process. The directed new share issue was subscribed for by several Swedish and international institutional investors. The investors were selected based on the accelerated bookbuilding procedure, which was carried out by Pareto Securities.
Sedana Medical AB is a Sweden-based medical technology company. It has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. It has direct sales in the Nordic countries, Germany, France, UK and Spain as well as external distributors in the rest of Europe, Canada, Australia and South Korea. The company headquarters are based in Stockholm, with R&D operations in Ireland.
Roschier’s advisory team comprised Pontus Enquist and Erik Persson from our Equity Capital Markets practice.